Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of five active ingredients commonly used as laxatives for the treatment of constipation and bowel preparation. The components are: - **Senna**: A stimulant laxative that increases peristalsis by direct action on the intestinal mucosa or nerve plexus. - **Docusate sodium**: A stool softener that lowers the surface tension of stool, allowing water and fats to penetrate and soften it. - **Bisacodyl**: Another stimulant laxative that acts directly on the colon to stimulate bowel movements. - **Magnesium hydroxide**: An osmotic laxative that draws water into the intestines, increasing stool bulk and triggering peristalsis. - **Polyethylene glycol 3350 (Miralax)**: An osmotic agent that retains water in the stool, resulting in softer stools and increased frequency of bowel movements[1][2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on senna + docusate sodium + bisacodyl + magnesium hydroxide + polyethylene glycol 3350.